Back to News​
Press Release

Alamar Biosciences Announces the Launch of the NULISAseq Mouse Panel 120

Back to Publications​
  • March 24, 2025

Providing the largest and most comprehensive, high sensitivity, protein biomarker analysis to advance pre-clinical research

Fremont, CA – March 24, 2025 – Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce the launch of the NULISAseq Mouse Panel 120, an innovative biomarker profiling solution that provides the most comprehensive coverage of protein targets for expression analysis in mouse models. Designed to facilitate biomedical research and pre-clinical development studies, this cutting-edge panel analyzes 120 proteins covering key pathways in inflammation, neurodegeneration and immuno-oncology. 

“The NULISAseq Mouse Panel 120 encompasses an unparalleled selection of proteins essential for studying key biological pathways in pre-clinical models” said Yuling Luo, Ph.D., Founder, Chairman and CEO of Alamar Biosciences. “This robust panel is designed specifically for mouse models enabling researchers to gain valuable insights into disease mechanisms and therapeutic efficacy”

With the broadest coverage of mouse protein targets, the NULISAseq Mouse Panel 120 is the only multiplex panel to include a specific focus on neurology content. This is crucial for researchers studying neurodegenerative diseases and the neurological effects of potential treatments.

“I’m excited to incorporate the NULISAseq Mouse Panel 120 panel into my research studies.” said Cheryl Wellington, Ph.D., Professor, Department of Pathology and Laboratory Medicine at University of British Columbia.  “This state-of-the art panel provides me with the broadest view of neuro-physiology and has the potential to uncover new insights into the mechanisms of dementia and traumatic brain injury.”

Built on Alamar’s novel multiplexing technology, the NULISAseq Mouse Panel 120 offers researchers a high-sensitivity, high-throughput solution to uncover complex biological mechanisms. The panel’s attomolar (fg/ml) sensitivity and 10 logs of dynamic range allows for the detection of a wide range of proteins found in mouse plasma, even those that are low in abundance, such as p-tau217, from as little as 5 µl sample input.

For more information, please visit alamarbio.com.

About Alamar Biosciences, Inc.

Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company’s proprietary NULISA™ Platform along with the ARGO™ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit alamarbio.com.

Linkedin

Steve Williams, MD, PhD

CSO

Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.

Linkedin

Justin McAnear

CFO

Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition.  He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.